Cirius Therapeutics Announces Presentation on CIR-0602K as Novel Diabetes Treatment at the American Diabetes Association's 2026 Scientific Sessions
GRAND RAPIDS, Mich., June 1, 2026 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced that clinical data on the treatment of type 2 diabetes (T2D) with...
GRAND RAPIDS, Mich., June 1, 2026 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced that clinical data on the treatment of type 2 diabetes (T2D) with...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.